Blockade of the lncRNA-PART1-PHB2 axis confers resistance to PARP inhibitor and promotes cellular senescence in ovarian cancer. Wu H, Sun C, Cao W, Teng Q, et al. Cancer Lett 2024;602:217192.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Wu H, Sun C, Cao W, Teng Q, et al. Blockade of the lncRNA-PART1-PHB2 axis confers resistance to PARP inhibitor and promotes cellular senescence in ovarian cancer. Cancer Lett 2024;602:217192.
PMID: 39181433